Indian CRO Syngene sets up Amgen R&D center in Bangalore

Syngene International, one of Asia’s biggest CROs and part of Biocon, has commissioned a new drug discovery and development center for Amgen in its native town of Bangalore, India.

The Syngene Amgen Research and Development Center (SARC) is now the fourth R&D hub coming out of Syngene, adding to its centers for Bristol-Myers Squibb ($BMY), Abbott Nutrition ($ABT) and Baxter ($BAX).

Described as “state-of-the-art,” its latest offering will be made up of around 100 Syngene scientists who will work hand-in-hand with Amgen researchers in India and around the world to help find and develop new meds.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Jonathan Hunt, CEO at Syngene, said: "We are delighted to announce the establishment of our dedicated R&D center for Amgen. Bringing together into one place, the range of activities we conduct on behalf of Amgen indicates the strategic nature of our relationship and also reflects the ability of Syngene’s scientific teams to deliver world-class science towards our partners’ R&D programs in both biotechnology and small molecule medicines.”

This further cements long-running ties between the two that see them already working on a series of discovery and development projects.

“With the establishment of SARC, this association now extends into a multi-discipline collaboration spanning capabilities in medicinal and process chemistry, biologics, bioprocess, drug metabolism, pharmacokinetics, bioanalytical research, and pharmaceutical development,” the CRO said in a statement. 

Suggested Articles

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get into this burgeoning area.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.